Silo Pharma posts investor presentation for Sep 2024 conference; notes SPC-15 pre-IND submitted

Silo Pharma, Inc.

Presentation used at H.C. Wainwright 26th Annual Global Investment Conference on Sep 10, 2024.
Lead asset SPC-15 (intranasal PTSD treatment) pre-IND submitted for first-in-human trials.
Pipeline also includes SP-26 (ketamine implant for fibromyalgia), SPC-14 (Alzheimer's), SPU-16 (MS).
Exclusive licenses from Columbia University (SPC-15, SPC-14) and University of Maryland (SPU-16).
Company intends to use 505(b)(2) regulatory pathway for SPC-15 and SP-26 to shorten timelines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.